Bibliografía
1. Kirsner JB. Historical origins of medical and surgical therapy of inflammatory bowel disease. The Lancet. octubre de 1998;352(9136):1303-5.
2. Caprilli R, Cesarini M, Angelucci E, Frieri G. The long journey of salicylates in ulcerative colitis: The past and the future. J Crohns Colitis. septiembre de 2009;3(3):149-56.
3. Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin N Am. febrero de 2016;42(1):1-14.
4. Kirsner JB. Historical origins of current IBD concepts. World J Gastroenterol. 2001;7(2):175.
5. Leavy O. The birth of monoclonal antibodies. Nat Immunol. diciembre de 2016;17(S1):S13-S13.
6. Vilcek J. From IFN to TNF: a journey into realms of lore. Nat Immunol. junio de 2009;10(6):555-7.
7. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Ther Adv Gastroenterol. enero de 2021;14:175628482110599.
8. Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, et al. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. enero de 2019;17(1):130-138.e7.
9. Kawalec P, Moćko P, Malinowska-Lipien I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: a systematic review and meta-analysis. J Comp Eff Res. octubre de 2017;6(7):601-12.
10. Gert VA, Marc VR, Raf S, Bénédicte D, Séverine V, Maja N, et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease. N Engl J Med. 2005;
11. D’Haens GR, Van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. julio de 2021;70(7):1396-405.
12. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. diciembre de 2017;390(10114):2769-78.
13. Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. mayo de 2023;8(5):458-92.
14. Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. febrero de 2022;55(4):464-78.
15. Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. The Lancet. junio de 2021;397(10292):2372-84.
16. Loftus EV, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, et al. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. Clin Gastroenterol Hepatol. agosto de 2023;21(9):2347-2358.e6.
17. Loftus EV, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 25 de mayo de 2023;388(21):1966-80.
18. D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. The Lancet. mayo de 2022;399(10340):2015-30.
19. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. The Lancet. mayo de 2022;399(10340):2031-46.
20. Sands BE, D’Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 9 de marzo de 2024;izae024.
21. Sandborn WJ, D’Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, et al. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. mayo de 2022;162(6):1650-1664.e8.
22. Sandborn WJ, Feagan BG, D’Haens G, Wolf DC, Jovanovic I, Hanauer SB, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 30 de septiembre de 2021;385(14):1280-91.
23. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. abril de 2023;401(10383):1159-71.
24. Mahmud O, Fatimi AS, Mahar MU, Jahangir A, Abbas M, Berinstein JA. Sphingosine 1-Phosphate Receptor Modulators are Effective in Patients With Moderately to Severely Active Ulcerative Colitis and a Prior Biologic Exposure: A Meta-Analysis of Randomized Controlled Trials. Clin Gastroenterol Hepatol. mayo de 2024;22(5):1139-1141.e3.
25. Chang S, Murphy M, Malter L. A Review of Available Medical Therapies to Treat Moderate-to-Severe Inflammatory Bowel Disease. Am J Gastroenterol. enero de 2024;119(1):55-80.
26. Ekman N, Giezen TJ, Andrea P, Weise M, Wolff-Holz E, Thorpe R, et al. Roundtable on biosimilars with European regulators and medical societies. Generics Biosimilars Initiat J. 2016;
27. Abramson A, Frederiksen MR, Vegge A, Jensen B, Poulsen M, Mouridsen B, et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol. enero de 2022;40(1):103-9.
28. Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. Net Remission Rates with Biologic Treatment in Crohn’s Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. mayo de 2023;21(5):1348-50.
29. Kayal M, Posner H, Spencer E, Colombel JF, Stalgis C, Ungaro RC. Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. diciembre de 2023;21(13):3433-3436.e1.
30. Bretto E, Ribaldone DG, Caviglia GP, Saracco GM, Bugianesi E, Frara S. Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies. Biomedicines. 11 de agosto de 2023;11(8):2249.
31. Kotze PG, Vermeire S. Upgrading therapeutic ambitions and treatment outcomes. Nat Rev Gastroenterol Hepatol. febrero de 2024;21(2):84-5.
32. Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, et al. What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study. J Crohns Colitis. 3 de abril de 2023;17(3):379-88.
33. Stidham RW, Vickers A, Singh K, Waljee AK. From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD? Gut. junio de 2022;71(6):1046-7.
34. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. N Engl J Med. 18 de julio de 2024;391(3):213-23.
35. Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. mayo de 2024;9(5):415-27.
36. Shouval DS, Rufo PA. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. JAMA Pediatr. 1 de octubre de 2017;171(10):999.
37. Michaudel C, Danne C, Agus A, Magniez A, Aucouturier A, Spatz M, et al. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut. julio de 2023;72(7):1296-307.
38. Benech N, Sokol H. Targeting the gut microbiota in inflammatory bowel diseases: where are we? Curr Opin Microbiol. agosto de 2023;74:102319.
39. Riggott C, Mikocka-Walus A, Gracie DJ, Ford AC. Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. octubre de 2023;8(10):919-31.
40. Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, et al. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis. N Engl J Med. 8 de febrero de 2024;390(6):510-21.
41. Clough JN, Omer OS, Tasker S, Lord GM, Irving PM. Regulatory T-cell therapy in Crohn’s disease: challenges and advances. Gut. mayo de 2020;69(5):942-52.
42. Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. noviembre de 2021;19(11):2324-2332.e6.
43. Allegretti JR, Mitsialis V, Canavan JB, Snapper SB, Hamilton M, Barends J, et al. Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis. Gastroenterology. agosto de 2023;165(2):492-495.e2.
44. Vermeire S, Solitano V, Peyrin-Biroulet L, Tilg H, Danese S, Ehrlich H, et al. Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. J Crohns Colitis. 8 de noviembre de 2023;17(10):1689-97.
45. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. The Lancet. noviembre de 2023;402(10416):2034-44.
46. Scott BM, Gutiérrez-Vázquez C, Sanmarco LM, Da Silva Pereira JA, Li Z, Plasencia A, et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease. Nat Med. julio de 2021;27(7):1212-22.
47. Zhang S, Ermann J, Succi MD, Zhou A, Hamilton MJ, Cao B, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci Transl Med [Internet]. 12 de agosto de 2015 [citado 24 de abril de 2024];7(300). Disponible en: https://www.science.org/doi/10.1126/scitranslmed.aaa5657
48. Calvet X, Panés J, Gallardo-Escudero J, De La Cuadra-Grande A, Bartolomé E, Marín L, et al. Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain. J Crohns Colitis. 23 de noviembre de 2022;16(11):1663-75.
49. Abreu MT, Kosinski LR. How Did It Get So Difficult to Care for Patients With Inflammatory Bowel Disease? Am J Gastroenterol. julio de 2024;119(7):1287-8.
50. Sebastian S, Siegmund B, Teferra F, McGovern DPB, Queiroz NSF, Van Der Woude CJ, et al. Promoting equity in inflammatory bowel disease: a global approach to care. Lancet Gastroenterol Hepatol. marzo de 2024;9(3):192-4.
51. Lange KW. Rudolf Virchow, poverty and global health: from “politics as medicine on a grand scale” to “health in all policies”. Glob Health J. septiembre de 2021;5(3):149-54.